<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01526278</url>
  </required_header>
  <id_info>
    <org_study_id>YY_PK_2011</org_study_id>
    <nct_id>NCT01526278</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Maxmarvil® in Healthy Postmenopausal Women</brief_title>
  <acronym>YY_PK_2011</acronym>
  <official_title>Pharmacokinetics of a Single Oral Dose of Maxmarvil® in Healthy Postmenopausal Women Without a Previous History of Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuyu Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuyu Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate clinical safety and pharmacokinetics of Maxmarvil® in healthy&#xD;
      postmenopausal women&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacokinetics of a single Oral Dose of Maxmarvil® in healthy postmenopausal women without&#xD;
      a previous history of fractures&#xD;
&#xD;
        1. evaluation of Pharmacokinetics&#xD;
&#xD;
             -  Urine collection : Pre-dose(pre 1hour), post-dose 0~6 hour, 6~12 hour, 12~24 hour&#xD;
&#xD;
             -  Evaluation Variables : Aet&#xD;
&#xD;
        2. Evaluation of safety, pharmacodynamics&#xD;
&#xD;
             -  Adverse Event : check it every and frequently&#xD;
&#xD;
             -  Physical exam : screening, just before injection, post-dose 24 hour and post-study&#xD;
                visit&#xD;
&#xD;
             -  Vital sign : screening, just before injection, post-dose 1 hour, 24 hour and&#xD;
                post-study visit&#xD;
&#xD;
             -  Laboratory test : screening, post-dose 24hour&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>analysis of Alendronate concentrate</measure>
    <time_frame>pre-dose, post dose 0-6hour, 6-12hour, 12-24hour</time_frame>
    <description>If the CrCL value is less than 75%, it is considered that collected urine is not appropriate and collected urine is exclusived for analysis of pharmacokinetics</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Maxmarvil®</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>single-arm study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maxmarvil®</intervention_name>
    <description>Drug : Maxmarvil® 1tablet one time in clinical trial, PO medication</description>
    <arm_group_label>Maxmarvil®</arm_group_label>
    <other_name>Alendronate 5mg + calcitriol 0.5 μg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Screening test in healthy postmenopausal women without a previous history of fracture&#xD;
&#xD;
          -  Normal range in laboratory test arranged by principal investigator because of the&#xD;
             character of medicine&#xD;
&#xD;
          -  over 50kg, body weight is in ± 20% of ideal body weight Written concent by himself and&#xD;
             following the protocol after understanding of the explained clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject who have taken something to induce and inhibit the drug metabolizing enzyme&#xD;
             within 1 month like Barbiturate.&#xD;
&#xD;
          -  Subject who have a history of drug abuse and got a positive in urine test for drug&#xD;
             abuse.&#xD;
&#xD;
          -  Subject who have taken a prescription only medicine or an oriental medicine within 2&#xD;
             weeks after first administration the clinical drug trial , taken a OTC within 1 week&#xD;
             after first administration the clinical drug trial like some OTC including calcium, an&#xD;
             antacids, multiple vitamin, mineral.&#xD;
&#xD;
          -  Subject who have been chronic drinking(over 21 units/week) or can not stop drinking&#xD;
             during the clinical trial.&#xD;
&#xD;
          -  Subject who have smoked over 10 unit/day for 3months.&#xD;
&#xD;
          -  Subject who have light or clear hypersensitivity reaction about OTC(aspirin,&#xD;
             antibiotic medication) or bisphosphonates(alendronate)&#xD;
&#xD;
          -  Subject who have got a disease about liver, kidney, neurology, respiratory, endocrine,&#xD;
             hematooncology, cardiovascular, musculoskeletal, psychological or history of fracture&#xD;
             within 12months or a tooth extraction within 6month&#xD;
&#xD;
          -  Subject who have a history of gastrointestinal disease or stomach surgery without&#xD;
             appendectomy, herniotomy having an effort the absorb of clinical drug trial.&#xD;
&#xD;
          -  Subject who have a esophageal disease like esophagitis, esophageal ulcer, esophagus&#xD;
             erosion, esophagorrhaphy, esophagostenosis, dysphagia.&#xD;
&#xD;
          -  Subject who can not keep the sitting position for 30minutes&#xD;
&#xD;
          -  Subject who is out of normal range of calcium concentration in blood (8.8 ~ 10.5&#xD;
             mg/dl)&#xD;
&#xD;
          -  Subject who is hypotension(systolic blood pressure ≤ 90mmHg or diastolic blood&#xD;
             pressure ≤ 50 mmHg ) or hypertension(systolic blood pressure ≥ 150mmHg or diastolic&#xD;
             blood pressure ≥ 100 mmHg ) in sitting position after rest 3 minutes&#xD;
&#xD;
          -  join the other clinical trial within 2months after administration of the clinical drug&#xD;
             trial.&#xD;
&#xD;
          -  Subject who have donated whole blood within 2 months or plasma within 1 month.&#xD;
&#xD;
          -  Subject who have a grapefruit and something including caffeine in close season(from 3&#xD;
             days before administration to discharge from the hospital )&#xD;
&#xD;
          -  For the result of laboratory and the other reason subject is considered unsuitable by&#xD;
             principal's decision&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yoon-suk chung, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou university hospotal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 1, 2012</study_first_submitted>
  <study_first_submitted_qc>February 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2012</study_first_posted>
  <last_update_submitted>February 21, 2019</last_update_submitted>
  <last_update_submitted_qc>February 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alendronate</keyword>
  <keyword>Maxmarvil®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
    <mesh_term>Maxmarvil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

